Yüklüyor......
Symptomatic Rebound Hypercalcemia After Denosumab Discontinuation in a Pediatric Patient With Cherubism
Background: Pediatric bone diseases due to osteoclast overactivity have limited therapeutic options. Denosumab, a human monoclonal antibody against RANK-ligand, has been used in the treatment of these conditions despite limited pediatric safety data. Rebound hypercalcemia after denosumab cessation i...
Kaydedildi:
| Yayımlandı: | J Endocr Soc |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8089891/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1439 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|